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Abstract. Rosehip, the fruit of Rosa canina L., has tradition-
ally been used to treat urate metabolism disorders; however, 
its effects on such disorders have not been characterized in 
detail. Therefore, the present study investigated the effects 
of hot water, ethanol and ethyl acetate extracts of rosehip 
on xanthine oxidase (XO) activity in vitro. In addition, the 
serum urate lowering effects of the rosehip hot water extract 
in a mouse model of hyperuricemia (male ddY mice, which 
were intraperitoneally injected with potassium oxonate) were 
investigated. Furthermore, the influence of rosehip hot water 
extract on CYP3A4 activity, which is the most important 
drug-metabolizing enzyme from a herb-drug interaction 
perspective, was investigated. Rosehip extracts of hot water, 
ethanol and ethyl acetate inhibited XO activity [half maximal 
inhibitory concentration (IC50) values: 259.6±50.6, 242.5±46.2 
and 1,462.8±544.2 µg/ml, respectively]. Furthermore, the 
administration of 1X rosehip hot water extract significantly 
reduced the levels of serum urate at 8 h, which was similar 
when compared with the administration of 1 mg/kg allopurinol. 
Rosehip hot water extract only marginally affected CYP3A4 
activity (IC50 value, >1 mg/ml). These findings indicate that 
rosehip hot water extract may present as a functional food for 
individuals with a high urate level, and as a therapeutic reagent 
for hyperuricemic patients.
Introduction
Certain types of food exert beneficial effects on human health; 
however, the effects are not explained by the nutritional content, 
such as macronutrients, vitamins and minerals (1). These types 
of food, termed functional foods, are food-derived products 
that enhance normal physiological or cognitive functions, or 
prevent the abnormal function that underlies disease (1). These 
food types also contribute to the promotion of self-medication, 
i.e., the use of over-the-counter medicines, including herbal 
and traditional products, to treat self-recognized illnesses or 
symptoms (1,2). Of particular interest is the biological activity 
and safety of natural products, including food, traditional 
herbs, kampo and their phytochemicals (3-13).
Rosehip is the fruit of rose plants within the genus Rosa, in 
particular Rosa canina L., also termed dog rose. Rosehip has a 
particularly high vitamin C content compared with other fruits 
and vegetables (14,15), and contains other vitamins, minerals, 
sugars, fatty acids and flavonoids (14). Rosehip has traditionally 
been administered for the treatment of colds, infectious diseases 
and inflammatory diseases (16). In support of its traditional 
uses, various studies have reported that rosehip exhibited bioac-
tivity, including antioxidant (17,18), anti‑inflammatory (19‑22), 
hepatoprotective (23), anti-diabetic (17) and anti-obesity (24) 
effects. Therefore, rosehip may be considered a functional food 
that promotes health. Although rosehip has traditionally been 
administered for treating uric acid (urate) metabolism disor-
ders (16), its effects have not been characterized in detail.
In humans, urate is the end product of purine metabo-
lism and is delivered from hypoxanthine following double 
enzyme catalysis by xanthine oxidase (XO) in the liver (25). 
Serum urate production is regulated by the endogenous (de 
novo purine synthesis and tissue catabolism under normal 
circumstances) and exogenous (diet including animal protein) 
precursor proteins delivered to the liver; whereas its excre-
tion is controlled by the kidneys through renal plasma flow, 
glomerular filtration and proximal tubular exchange (26,27). 
The imbalance of its production and excretion induces hyper-
uricemia, which also develops into gout and kidney stones, 
and accelerates the progression of renal and cardiovascular 
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diseases (28,29). Potassium oxonate (PO)-treated mice gener-
ally serve as a model of urate overproduction (hyperuricemia), 
as its intraperitoneal injection induces the overproduction 
of urate in mice (30-33). Indeed, a previous study using 
PO-treated ABCG2-knockout mice reported that a decrease 
of extra-renal urate excretion was one of the most common 
causes of hyperuricemia (33).
Numerous studies have demonstrated that the simultaneous 
administration of a food or beverage that inhibits drug-metab-
olizing enzymes, such as cytochrome P450 (CYP), and a drug 
that is metabolized by said enzyme alters blood concentrations, 
although occasionally with adverse effects (34). A phenomenon 
similar to this food-drug interaction can be generated between 
food and drugs. Indeed, it has previously been demonstrated 
that beverages and food, such as beer, red wine, black and 
herbal tea, garlic, spices, mace, nutmeg, fruit and fruit juice, 
tomato juice, and licorice root inhibited enzyme-mediated 
drug metabolism (9,10,35-39). Although rosehip has been used 
as a food and as a traditional medicine (16), to the best of our 
knowledge, there is no evidence of an interaction between 
rosehip and CYP3A4-metabolizing drugs.
In the present study, the effects of hot water, ethanol 
and ethyl acetate extracts of rosehip on XO activity were 
investigated in an in vitro assay. In addition, the effect of 
rosehip hot water extract on urate metabolism was evaluated 
according to the level of serum urate in hyperuricemia model 
mice. Furthermore, whether rosehip hot water extract inhibits 
CYP3A4 activity in vitro was investigated.
Materials and methods
Materials. Unless otherwise stated, the various reagents 
and the Urate C-test Wako kit were purchased from Wako 
Pure Chemical Industries, Ltd. (Osaka, Japan). Rosehip was 
obtained from the Tree of Life Co. (Tokyo, Japan). Xanthine 
oxidase (from buttermilk), nicotinamide adenine dinucleotide 
phosphate oxidized form (β-NADP+), glucose-6-phosphate 
(G-6-P), and G-6-P dehydrogenase (G-6-PDH) were purchased 
from Oriental Yeast, Ltd. (Tokyo, Japan). Dimethyl sulfoxide 
(DMSO) and 11α-hydroxyprogesterone were purchased 
from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). 
Human CYP3A4R Bactosomes (recombinant CYP3A4) 
were purchased from Cypex Ltd. (Scotland, UK). Mightysil 
RP-18 GP 250-4.6 (5 µm) [Octadecylsilyl (ODS) column] was 
purchased from Kanto Chemical, Co., Inc. (Tokyo, Japan).
Preparation of rosehip hot water extract. The extract was 
prepared from triturated powder (1 g) with 20 ml MilliQ-water 
at room temperature and decocted at 100˚C for 30 min. The 
extract was cooled, filtered and evaporated using a freeze 
dryer, after which the dried sample (yield, 65.2%) was weighed 
and dissolved at a concentration of 50 mg/ml in MilliQ-water.
Preparation of rosehip ethanol or ethyl acetate extracts. The 
extracts were prepared from triturated powder (1 g) with 20 ml 
ethanol or ethyl acetate and agitated at room temperature for 2 h. 
The extracts, with ethanol or ethyl acetate, were subsequently 
filtered and evaporated, after which the dried samples were 
weighed (yields, 5.66 and 0.85%, respectively) and prepared at 
a concentration of 50 or 100 mg/ml in DMSO, respectively.
Measurement of XO activity in vitro. The measurement of XO 
activity was performed in accordance with previously published 
methods with modifications (40). Briefly, 151.5 µl Tris-HCl 
buffer (pH 7.5; 100 mM), 7.5 µl XO (0.4 U/m) in 50 mM Tris-HCl 
buffer (pH 7.5), and 9 µl rosehip extracts [concentrations, 10, 20, 
50 and 100 mg/ml (final concentrations, 500, 1,000, 2,500 and 
5,000 µg/ml, respectively) in the ethyl acetate extract, and 0.5, 
1, 5, 10, 50 mg/ml (final concentrations, 25, 50, 250, 500 and 
2,500 µg/ml, respectively) in the hot water and ethanol extracts] 
were mixed in 1.5-ml tubes. These tubes were pre-incubated in 
a heat‑block at 37˚C for 5 min. Subsequently, 12 µl xanthine 
(80 µM) in 25 mM NaOH was added and incubated at 37˚C 
for 30 min. The tubes were incubated at 100˚C for 1 min to 
terminate the reaction. To measure the quantities of urate 
production, the Urate C-test Wako kit was used according to the 
manufacturer's protocol. The relative XO activity was expressed 
as a ratio of the absorbance of each rosehip extract group to 
that of the corresponding vehicle control group (MilliQ-water 
or DMSO). The half maximal inhibitory concentration (IC50) 
values were calculated from the XO activity curves.
Animals. All experiments and the care and handling of the 
animals were approved by Josai University (Sakado, Japan) 
Institutional Animal Care and Use Committee. Thirty male 
ddY mice (age, 5 weeks), obtained from Sankyo Labo Service 
Corporation, Inc. (Tokyo, Japan) were used. The mice were 
housed in six cages with five mice per cage. They were exposed 
to a 12-h light/dark cycle and maintained at a constant temper-
ature of 22±2˚C and humidity of 55±10%. The mice were 
allowed 1 week to adapt to the laboratory environment prior to 
the experiments and fed laboratory pellet chow (CE-2; CLEA 
Japan Inc., Tokyo, Japan) and water ad libitum. All mice were 
euthanized by the intraperitoneal injection of pentobarbital 
sodium following completion of the experiments.
Treatment of hyperuricemia model mice with rosehip hot 
water extracts and allopurinol PO, a uricase inhibitor, was used 
to establish the hyperuricemia model mice, as described previ-
ously (30‑33). Briefly, pellet chow and water supplies to the ddY 
mice (age, 6 weeks; body weight, 31.0±0.37 g) were halted the 
night before the experiment. The mice were randomly divided 
into five groups (n=7 in the control group; n=5 in the 5 mg/ml 
allopurinol group; and n=6 in the 1 mg/ml allopurinol, 0.5X 
Figure 1. Diagram of the timeline of treatment with rosehip hot water extracts 
and allopurinol in the hyperuricemia model mice.
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or 1X rosehip hot water extract groups. The mice were treated 
with PO in 0.5% CMC-Na (280 mg/kg, i.p.) 1 h before oral 
administration of 5 ml/kg MilliQ-water (as the control group), 
1 or 5 mg/kg allopurinol, or 5 ml/kg of 0.5X or 1X rosehip hot 
water extract (~82.5 and ~165 mg/kg, respectively). A diagram 
of the timeline of the experiment is presented in Fig. 1.
Measurement of serum urate. Blood samples (0.1 ml) were 
collected into 0.6-ml tubes sequentially at 2, 4, 6 and 8 h via 
a small incision in the tail vein using a razor blade. The blood 
samples were incubated for 1 h at room temperature and centri-
fuged at 800 x g at 4˚C for 15 min. The supernatant (~20 µl) 
from each blood sample was collected as serum samples and 
stored at ‑20˚C until use. The quantity of serum urate in 3.3 µl 
of each serum sample was measured using the Urate C-test 
Wako kit, according to the manufacturer's protocol.
Measurement of CYP3A4 activity in vitro. Measurement of 
CYP3A4 activity was performed according to a previously 
described method (10). Briefly, 125 µl NADPH regenerating 
system [2.6 mM β-NADP+, 6.6 mM G-6-P and 6.6 mM MgCl2 
in 400 mM potassium phosphate buffer (pH 7.4)], 12.5 µl 
G-6-PDH (4 U/ml) in 100 mM Tris-HCl buffer (pH 7.4), 2.5 µl 
recombinant CYP3A4 (1.0 nmol/ml), 3.75 µl rosehip hot water 
extracts [concentrations, 0.8, 7.4, 22.2, 44.4 and 66.7 mg/ml 
(final concentrations, 12, 111, 333, 666 and 1,000 µg/ml, respec-
tively)], and 105 µl MilliQ-water were mixed and preincubated 
at 37˚C for 10 min. The reaction was initiated by the addition 
of 1.25 µl testosterone (60 mM). The reaction was terminated 
by the addition of 500 µl 11α-hydroxyprogesterone (10 µM) 
to the ethyl acetate after 15 min. Following centrifugation 
(15,000 x g for 5 min), 400 µl supernatant was collected, dried 
and suspended in 200 µl methanol. Analyses of the metabolite, 
6β-hydroxytestosterone, were performed using a high-perfor-
mance liquid chromatography (HPLC) system (PU-2089, 
UV-2075 and AS-2057; JASCO Corp., Tokyo, Japan) equipped 
with an ODS column. The mobile phase consisted of 70% (v/v) 
methanol and the metabolites were separated at a flow rate of 
1.0 ml/min. Quantification of the metabolite was performed 
by comparing the HPLC peak area at 254 nm to that of 
11α-hydroxyprogesterone, the internal standard. The retention 
times for 6β-hydroxytestosterone, 11α-hydroxyprogesterone 
and testosterone were ~4.3, ~6.2 and ~8.6 min, respectively. 
The relative CYP3A4 activity was expressed as the ratio of the 
HPLC peak area of each rosehip extract group to that of the 
corresponding vehicle (MilliQ-water) control group.
Statistical analysis. Statistical analysis was performed using 
the software BellCurve for Excel Ver. 2.1 (Social Survey 
Research Information Co., Ltd., Tokyo, Japan). After applying 
a rejection test, data were analyzed using Student's t-test and 
P<0.05 was considered to indicate a statistically significant 
difference. Data are reported as means ± standard deviation 
in vitro and as means ± standard error of the mean in vivo.
Results
Dose‑dependent effects of rosehip extracts on XO activities. 
To investigate the XO inhibitory effects of rosehip extracts, 
the XO activity was assessed in vitro. Significant decreases 
in XO activity were observed in a dose-dependent manner for 
the hot water, ethanol and ethyl acetate extracts (Fig. 2A-C, 
Figure 2. Effect of rosehip extracts on XO activity. (A) Hot water extract, (B) ethanol extract, and (C) ethyl acetate extract of rosehip dose-dependently reduced 
XO activity. (D) The IC50 values of each extract were calculated and compared. Data are reported as means ± standard deviation. *P<0.05 vs. ethyl acetate 
extraction. XO, xanthine oxidase; IC50, half maximal inhibitory concentration.
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respectively). As shown in Fig. 2D, the IC50 values were 
259.6±50.6, 242.5±46.2 and 1,462.8±544.2 µg/ml, respectively. 
These values differed significantly between the ethyl acetate 
extract, and the hot water or ethanol extract groups (P<0.05; 
Fig. 2D).
Effects of rosehip hot water extract on serum urate levels 
in hyperuricemic mice. All mice were healthy prior to the 
experiment and adverse events were not detected during the 
experiment itself. Treatment with PO, a uricase inhibitor, 
caused hyperuricemia in the mice, as indicated by a significant 
increase in serum urate levels at 4, 6, and 8 h (P<0.05; Fig. 3). 
The levels of serum urate upon administration of 5 mg/kg 
allopurinol (the 5 mg/kg allopurinol group) were significantly 
lower when compared with time 0 (P<0.05 at 6 h; P<0.01 at the 
other time-points) and compared with the levels in the control 
groups at each time-point (P<0.01). The levels of serum urate 
upon administration of 1 mg/kg allopurinol (the 1 mg/kg allo-
purinol group) and 1X rosehip hot water extract (1X rosehip 
extract group) were significantly lower at 2 h than at time 0 
(P<0.05), however, did not change at 4, 6 and 8 h. Furthermore, 
these levels were significantly lower than the levels in the 
control group (P<0.01), although there was no difference in 
these levels at each point between the 1 mg/kg allopurinol 
group and the 1X rosehip extract group (P>0.05). The levels 
of serum urate upon administration of 0.5X rosehip hot water 
extract (the 0.5X rosehip extract group) were significantly 
higher at 4, 6 and 8 h than at time 0 (P<0.05). Furthermore, 
these levels were significantly lower when compared with the 
levels in the control group at 8 h (P<0.01).
Effects of rosehip hot water extract on CYP3A4 activities. 
The addition of rosehip hot water extract tended to decrease 
the CYP3A4 activity in a dose-dependent manner, although 
this decrease was not significant (Fig. 4). Furthermore, at the 
highest examined concentration (1 mg/ml), rosehip hot water 
extract inhibited only 40% of CYP3A4 activity (IC50 value, 
>1 mg/ml).
Discussion
In the present study, it was demonstrated that each of the rosehip 
extracts obtained using hot water, ethanol, and ethyl acetate 
inhibited XO activity. The different methods of extracting 
rosehip also generated different strengths of inhibitory effect, 
namely, the hot water and ethanol extracts exhibited mark-
edly stronger dose-dependent inhibition of XO activity when 
compared with the ethyl acetate extract. Numerous studies have 
suggested that the particular polarity of an extraction solvent 
affects the biological activity of the extract (20,41,42); for 
example, the free radical scavenging activities associated with 
extracts of Galla chinensis, a traditional Chinese herb, were 
in the following order: Ethyl acetate (weak polarity) >ether 
polarity), because an antioxidant phytochemical, tannin, in 
this extract is soluble in non-polar or weak polar solvents (41). 
Certain studies have reported that polyphenols, flavonoids 
and saponins are potent XO inhibitors (43-46), and rosehip 
contains numerous phenolic phytochemicals (47). Taking 
these previous results and the observations of the current study 
into account, the difference in the inhibitory effect of rosehip 
extracts on XO activity may be associated with the polarity 
of the extraction solvent, and rosehip containing phenolic 
phytochemicals, the principal substances, are more likely to 
Figure 3. Levels of serum urate in hyperuricemic mice treated with vehicle, 1 mg/ml allopurinol, 5 mg/ml allopurinol, 0.5X rosehip extract, and 1X rosehip 
extract. Data are presented as means ± standard error of the mean. *P<0.05 and **P<0.01 vs. control group; †P<0.05 and ‡P<0.01 vs. each case at time 0.
Figure  4. Effect of rosehip extracts on CYP3A4 activity. Data are presented 
as means ± standard deviation.
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induce an inhibitory effect. Identification of the XO‑inhibiting 
constituents in rosehip is currently underway.
The end product of purine metabolism varies between 
species. In the majority of mammals, urate is converted to 
allantoin, a more soluble product that is easily excreted in 
the urine, by the enzyme uricase (also termed urate oxidase). 
However, uricase was lost in hominoids during primate 
evolution (25). To mimic the purine metabolism of humans 
who lack uricase, mice were exposed to PO, a uricase 
inhibitor (30-33). In the current study, the oral administration 
of hot water extract was selected in hyperuricemic mice, as 
rosehip has typically been used for herbal tea and this extract 
had a high yield when compared with extracts from other 
extraction methods. In addition, allopurinol, an XO inhibitor, 
was administered to serve as a positive control. The admin-
istration of 1 and 5 mg/kg allopurinol in hyperuricemic mice 
significantly and dose-dependently decreased the level of 
serum urate at each time-point, indicating that each dose of 
allopurinol effectively inhibited XO activity in the hyperuri-
cemic mice. Furthermore, the administration of 1X rosehip 
extract reduced the increased serum urate level to the same 
extent as the administration of 1 mg/kg allopurinol. This is 
identical to the effect observed in the 1 mg/kg allopurinol 
group, suggesting that the inhibitory effect of 1X rosehip hot 
water extract on XO activity virtually mimicked the effect of 
1 mg/kg allopurinol.
CYP3A4 is considered to be the most important 
drug-metabolizing enzyme, as it metabolizes >50% of all 
clinical drugs (48). It is necessary to consider herb-drug 
interactions in order to use herbs safely (9,10,35-39). The 
present study attempted to determine whether rosehip hot 
water extract inhibited CYP3A4 activity. In the current study, 
although 12-1,000 µg/ml rosehip hot water extract tended 
to exhibit dose-dependent inhibition of CYP3A4 activity, 
it had a very weak effect. Therefore, the risk of interaction 
between rosehip hot water extract and CYP3A4 substrate 
drugs appears to be low. Furthermore, other studies reported 
that ethyl acetate, n-butanol and ethanol extracts from rosehip 
did not induce toxicity in an acute toxicity test in mice (20), 
and favorable results were obtained from clinical trials in 
osteoarthritis (49-51). Thus, the safety of rosehip has been 
confirmed by traditional experiences of its use, as well as by 
safety testing.
In conclusion, the current study has demonstrated for the 
first time, to the best of our knowledge, that hot water, ethanol 
and ethyl acetate extracts of rosehip inhibited XO activity 
in vitro and that this inhibitory effect was greater for the hot 
water and ethanol extracts. In addition, the oral administra-
tion of rosehip hot water extract decreased the levels of serum 
urate in hyperuricemic mice, as a result of the inhibition of 
XO activity. Notably, rosehip hot water extract exerted little 
effect on CYP3A4 activity. Collectively, these results indicate 
that rosehip hot water extract is a promising candidate as a 
functional food for individuals with a high urate level and as a 
therapeutic reagent of hyperuricemic patients.
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